Monopar Therapeutics (MNPR) Competitors

Monopar Therapeutics (NASDAQ:MNPR) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, community ranking, dividends, earnings, profitability and institutional ownership.

Does the media favor MNPR or CGEM?

In the previous week, Monopar Therapeutics had 4 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 5 mentions for Monopar Therapeutics and 1 mentions for Cullinan Therapeutics. Monopar Therapeutics' average media sentiment score of 0.59 beat Cullinan Therapeutics' score of 0.49 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals and insiders hold more shares of MNPR or CGEM?

1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 34.9% of Monopar Therapeutics shares are held by insiders. Comparatively, 6.1% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Is MNPR or CGEM more profitable?

Cullinan Therapeutics' return on equity of -26.54% beat Monopar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-107.21%	-87.57%
Cullinan Therapeutics	N/A	-26.54%	-25.32%

Which has more volatility & risk, MNPR or CGEM?

Monopar Therapeutics has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.14, suggesting that its stock price is 114% less volatile than the S&P 500.

Which has stronger valuation and earnings, MNPR or CGEM?

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$8.40M	-$1.97	-17.09
Cullinan Therapeutics	N/A	N/A	-$153.16M	-$2.84	-3.70

Does the MarketBeat Community believe in MNPR or CGEM?

Monopar Therapeutics received 2 more outperform votes than Cullinan Therapeutics when rated by MarketBeat users. However, 82.35% of users gave Cullinan Therapeutics an outperform vote while only 73.33% of users gave Monopar Therapeutics an outperform vote.

Company	Underperform	Outperform
Monopar Therapeutics	Outperform Votes 44 73.33%	Underperform Votes 16 26.67%
Cullinan Therapeutics	Outperform Votes 42 82.35%	Underperform Votes 9 17.65%

Do analysts recommend MNPR or CGEM?

Monopar Therapeutics currently has a consensus target price of $43.00, suggesting a potential upside of 27.71%. Cullinan Therapeutics has a consensus target price of $31.67, suggesting a potential upside of 201.30%. Given Cullinan Therapeutics' higher probable upside, analysts clearly believe Cullinan Therapeutics is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cullinan Therapeutics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Monopar Therapeutics and Cullinan Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.